1,721,102 research outputs found
The abilities of golimumab in the therapy of ankylosing spondylitis
Get PDFThe paper summarizes the data of the GO-RAISE trial evaluating the efficacy and tolerability of golimumab (GLM) in patients with ankylosing spondylitis (AS). The trial was launched in 57 clinical centers of North America, Europe, and Asia in 2005. It enrolled 356 patients with high AS activity (BASDAI≥4) in whom previous and current therapies with nonsteroidal anti-inflammatory drugs (NSAIDs) or disease-modifying anti-rheumatic drugs were ineffective. Group 1 patients received subcutaneous placebo; Group 2 had subcutaneous GLM 50 mg; Group 3 took GLM 100 mg every 4 weeks. Concomitant therapy with methotrexate, sulfasalazine, hydroxychloroquine, glucocorticoids, and NSAIDs was continued in previous doses. The investigators have concluded that GLM therapy in patients with AS gives rise to a rapid clinical and radiographic response that persists for a long time. Although no comparative trials of GLM versus other tumor necrosis factor-α (TNF-α) inhibitors used to treat AS have conducted, the available data show that its efficacy and tolerability in these patients are similar to those of the TNF-α inhibitors already used in Russia. The GLM dose of 100 mg is noted to be worse tolerated than that of 50 mg with their practically equal clinical efficacy. The standard dose of GLM is 50 mg subcutaneously administered once monthly for all indications, including also for AS
A NEW CONCEPT OF SPONDYLOARTHRITIS: A COMPROMISE BETWEEN ASAS AND GRAPPA?
Get PDFThe paper briefly discusses the history of spondyloarthritis (SpA) from the article published by J. Moll et al. in 1974 to the present day. The discussion of the recent SpA concept proposed by the Assessment of SpondyloArthritis International Society (ASAS), which divides this group of diseases into axial and peripheral types, by elaborating the appropriate criteria, holds a special position. This division could rapidly introduce the principles of early diagnosis of axial SpA on the one hand; however, it hinders their investigation as a genetically and clinically associated spectrum of diseases on the other hand
Features of the course and outcomes of COVID-19 in patients with axial spondyloarthritis
Get PDFThe 2019 coronavirus disease pandemic (COVID-19) is particularly challenging not only for doctors, but also for patients with inflammatory diseases, including spondyloarthritis. Although a large number of studies have been conducted over the past 2 years on the effect of COVID-19 on patients with rheumatic diseases, however, the conclusions from them are not always unambiguous. Given the growing number of cases of COVID-19 infection worldwide, there is a need to study the impact of individual diseases on its outcomes. The results of the study of COVID-19 in spondyloarthritis are limited to isolated reports of cases of the disease. Moreover, there is practically no literature devoted to the outcomes of COVID-19 exclusively in patients with axial spondyloarthritis. However, over the past few months, two large studies have been publishe d, in total, analyzing the outcomes of infection with SARS-CoV-2 in more than 14,000 patients with spondyloarthritis. The article discusses the results of these studies, the result of which is the conclusion that the presented data should convince both patients and doctors that axial spondyloarthritis and the therapy carried out for its treatment does not increase the risk of infection and does not aggravate the outcomes of COVID-19
«FLARES» IN AXIAL SPONDYLOARTHRITIS
Get PDFThe clear definition of the concept of «flare in axial spondyloarthritis» is of paramount importance for clinical trials and routine practice in particular. It will be able to unify the characteristics of outcomes over a particular period of time on the one hand and to standardize therapeutic approaches on the other. On 4 February 2016, the journal Annals of Rheumatic Diseases published the on-line paper «Preliminary definitions of 'flare' in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative» by L. Gossec et al., which was devoted to this topic
THE POSSIBILITIES AND RESULTS OF INDIRECT COMPARISON OF BIOLOGICAL AGENTS IN ANKYLOSING SPONDYLITIS
Get PDFThe paper analyzes two matching-adjusted indirect comparison-based investigations of the efficacy of adalimumab (ADA) and secukinumab (SCM) in active ankylosing spondylitis, which have been recently reported at the EULAR Congress (London, 2016). One study sponsored by AbbVie was conducted to determine the short-term (16-week) comparative clinical and economic efficacy of the test drugs and the other was supported by Novartis to reveal long-term (52-week), only clinical efficacy. Both studies have shown that the short-term efficacy ofADAand SCM is practically similar; however, the latter has a better long-term clinical efficacy. A pharmacoeconomic analysis of both drugs used during the first 12 weeks has demonstrated some advantage ofADA
PROBLEMS OF SPONDYLOARTHRITIS IN THE PROCEEDINGS OF THE EULAR-2013 CONGRESS (MADRID, 12–15 JUNE 2013)
Get PDFThe EULAR-2013 Congress took place in Madrid on 12–15 June 2013. The problem of spondyloarthritis (SA) was one of the significant aspects at this scientific forum. It should be primarily pointed out that the congress presented a T2T (treat-to-target) initiative to treat this disease. According to this concept, the main goal of SA therapy, as that for rheumatoid arthritis, is remission or low activity although there is no clear definition of these conditions in SA. A con- siderable amount of time was devoted to the results of recent SA pathogenesis investigations, including the role of interleukin 23. Discussions around the proposed SA classification concerning the criteria for mainly axial and periph- eral SAs and their clinical variety did not cease either. Reports on already well-known and novel treatment options and their efficiency during long term follow up held a prominent position at the congress
SPONDYLOARTHRITIS: EVOLUTION OF A CONCEPT
Get PDFA new concept in spondyloarthritis (SpA) aimed to ease the diagnosis of the early stages of the disease differentiates axial SpA without radiological signs of sacroiliitis and ankylosing spondilitis (AS). However, such division of the entire nosological entity into two is illogical. oreover, it contradicts International Statistical Classification of Diseases and Related Health Problems (ICD-10) and does not have a clinical proof (clinical data support), which was demonstrated in the work of E.E. Gubar et al. published in the present issue of the journal. Therefore it appears more reasonable to consider non-radiological axial SpA (with sacroiliitis confirmed by MRI) as an early stage of SpA
THE NEW VERSION OF T2T (TREAT-TO-TARGET) FOR SPONDYLOARTHRITIDES
Get PDFThe communication briefly presents the updated version of treat-to- target (T2T) recommendations for spondyloarthritides
CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
Get PDFThe paper gives the results of the RAPID-axSpA study that has evaluated for the first time the efficacy of the tumor necrosis factor-α (TNF-α) inhibitor certolizumab pegol (CZP) in treatment of axial spondyloarthritis (axSpA) clinical forms: already developed ankylosing spondylitis and non-radiographic axSpA. CZP was shown to be effective in all forms of axSpA, whether radiographically detected sacroiliitis was present or absent. This study has also demonstrated for the first time the long-term efficacy of TNF-α inhibitors in patients with initially high C-reactive protein level and/or signs of active sacroiliitis by magnetic resonance imaging
- …
